NCT03025022View on ClinicalTrials.gov

A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 17, 2017

Primary Completion Date

February 27, 2017

Study Completion Date

February 27, 2017

Conditions

Healthy

Interventions

DRUG

14C-JNJ-42847922 40 mg

Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.

Trial Locations (1)

Unknown

Madison

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT03025022 - A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects | Biotech Hunter | Biotech Hunter